Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 2, 2026, 2:27 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 776 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Attention placebo control Clear all
Completed Not applicable Interventional

TACTICS (Targeting Adherence to Cholesterol-lowering Therapy to Improve Control Study)

NCT01043354
View directory record Official record
Conditions
Hypercholesterolemia
Interventions
stage-matched intervention, framing effects intervention, attention placebo intervention
Behavioral
Lead sponsor
Narrows Institute for Biomedical Research
Other
Eligibility
21 Years and older
Enrollment
247 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 2, 2014 · Synced Oct 2, 2026, 2:27 AM EDT
Active, not recruiting Not applicable Interventional

Transcranial Direct Current Stimulation of the Temporal Cortex in Survivors of Childhood Acute Lymphoblastic Leukemia (ALL)

NCT04105530
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia, Transcranial Direct Current Stimulation, Executive Dysfunction
Interventions
Anodal tDCS treatment, Cathodal tDCS treatment, Sham treatment, NIH Toolbox List Sorting Working Memory Test, NIH Toolbox Flanker Inhibitory Control and Attention Test, Grooved Peg Board Test, Buschke Selective Reminding Test
Device · Other
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
8 Years to 215 Months
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 12, 2024 · Synced Oct 2, 2026, 2:27 AM EDT
Completed Phase 2 Interventional Results available

Controlled Study to Evaluate the Safety and Efficacy of Azficel-T for Vocal Fold Scarring and Age-Related Dysphonia

NCT02120781
View directory record Official record
Conditions
Dysphonia Resulting From Vocal Fold Scarring, Age-related Dysphonia
Interventions
Azficel-T (autologous fibroblasts), Placebo
Biological · Drug
Lead sponsor
Castle Creek Biosciences, LLC.
Industry
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
3
States / cities
Los Angeles, California • Stanford, California • New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 3, 2021 · Synced Oct 2, 2026, 2:27 AM EDT
Completed Phase 1 Interventional

Effect of Sublingual Formulation of Dexmedetomidine HCl (BXCL501) - Alcohol Interaction Study

NCT04827056
View directory record Official record
Conditions
Alcohol Use Disorder (AUD), Post Traumatic Stress Disorder (PTSD)
Interventions
Placebo, Dexmedetomidine (DEX) for sublingual (SL) administration (BXCL501) - 40µg, Dexmedetomidine (DEX) for sublingual (SL) administration (BXCL501) - 80µg, Ethanol Infusion, PTSD Reactivity Condition, Alcohol Cue Reactivity
Drug · Procedure · Behavioral
Lead sponsor
Pharmacotherapies for Alcohol and Substance Use Disorders Alliance
Other
Eligibility
21 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
West Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Oct 26, 2023 · Synced Oct 2, 2026, 2:27 AM EDT
Completed Phase 3 Interventional Results available

Phase 3 Efficacy and Safety Fixed-Dose Study in Pediatrics (6-17) With ADHD Using CTx-1301

NCT05286762
View directory record Official record
Conditions
ADHD, Attention Deficit Hyperactivity Disorder, ADHD - Combined Type, Attention Deficit Hyperactivity Disorder Combined, Attention-deficit Hyperactivity, Attention Deficit Hyper Activity
Interventions
CTx-1301-Dexmethylphenidate 12.5 mg (titration only), CTx-1301-Dexmethylphenidate 18.75mg (randomized fixed dose), CTx-1301-Dexmethylphenidate 25mg (randomized fixed dose), CTx-1301-Dexmethylphenidate 37.5 mg (randomized fixed dose), Placebo
Drug
Lead sponsor
Cingulate Therapeutics
Industry
Eligibility
6 Years to 17 Years
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
24
States / cities
Jacksonville, Florida • Maitland, Florida • Orlando, Florida + 21 more
Source: ClinicalTrials.gov public record
Updated Jan 22, 2026 · Synced Oct 2, 2026, 2:27 AM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

Effect of Dexmedetomidine on the Minimum Alveolar Concentration of Sevoflurane

NCT03384563
View directory record Official record
Conditions
Pediatric Anesthesia
Interventions
Dexmedetomidine
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
1 Month to 36 Months
Enrollment
180 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2025
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 22, 2025 · Synced Oct 2, 2026, 2:27 AM EDT
Completed Phase 2 Interventional Results available

Fibroblast Growth Factor Regeneration of Tympanic Membrane Perforations

NCT02307916
View directory record Official record
Conditions
Tympanic Membrane Perforation
Interventions
FGF-2, Placebo
Drug · Other
Lead sponsor
D. Bradley Welling, MD, PhD
Other
Eligibility
18 Years and older
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
2
States / cities
Boston, Massachusetts • Lackland City, Texas
Source: ClinicalTrials.gov public record
Updated Dec 8, 2025 · Synced Oct 2, 2026, 2:27 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effect of Bright Light Treatment On Elders In a Long Term Care Environment

NCT01042587
View directory record Official record
Conditions
Behavioral Responses to Bright Light Therapy in Elders
Interventions
exposure to bright light, low luminosity red light
Other
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
65 Years and older
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Elizabethtown, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 11, 2010 · Synced Oct 2, 2026, 2:27 AM EDT
Completed Phase 2 Interventional Results available

A Controlled Trial of Serotonin Reuptake Inhibitors Added to Stimulant Medication in Youth With Severe Mood Dysregulation

NCT00794040
View directory record Official record
Conditions
Mood Disorder, Mental Disorder Diagnosed in Childhood, Attention Deficit and Disruptive Behavior Disorder, Attention Deficit Hyperactivity Disorder
Interventions
Add-on citalopram following optimized methylphenidate, Add-on placebo following optimized methylphenidate
Drug
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
7 Years to 17 Years
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2018
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated May 7, 2019 · Synced Oct 2, 2026, 2:27 AM EDT
Active, not recruiting Phase 3 Interventional Results available

A Study of Different Donanemab (LY3002813) Dosing Regimens in Adults With Early Alzheimer's Disease (TRAILBLAZER-ALZ 6)

NCT05738486
View directory record Official record
Conditions
Alzheimer's Disease, Dementia, Brain Diseases, Central Nervous System Diseases, Nervous System Diseases, Neurodegenerative Diseases, Neurocognitive Disorders, Mental Disorders
Interventions
Donanemab, Placebo, Dexamethasone
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
60 Years to 85 Years
Enrollment
1,175 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
43
States / cities
Chandler, Arizona • Irvine, California • Long Beach, California + 38 more
Source: ClinicalTrials.gov public record
Updated Jun 18, 2026 · Synced Oct 2, 2026, 2:27 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

HELP-HY: Health Education and sLeep Program in HYpertension

NCT03255746
View directory record Official record
Conditions
Prehypertension, Hypertension
Interventions
Sleep Enhancement, Health Education
Behavioral
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 65 Years
Enrollment
110 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2025
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Oct 2, 2026, 2:27 AM EDT
Completed Phase 3 Interventional Results available

Clobetasol Propionate Ophthalmic Nanoemulsion 0.05% for the Treatment of Inflammation and Pain Associated With Cataract Surgery (CLOSE-2)

NCT04249076
View directory record Official record
Conditions
Cataract
Interventions
Clobetasol Propionate, Vehicle
Drug
Lead sponsor
Salvat
Industry
Eligibility
18 Years and older
Enrollment
215 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
18
States / cities
Sun City, Arizona • Hemet, California • Inglewood, California + 15 more
Source: ClinicalTrials.gov public record
Updated Dec 22, 2022 · Synced Oct 2, 2026, 2:27 AM EDT
Recruiting Phase 4 Interventional

Measuring the Effect of Dupilumab Treatment on Mucociliary Clearance (MCC) in Subjects With Moderate to Severe Asthma

NCT04743791
View directory record Official record
Conditions
Asthma
Interventions
Dupilumab, Placebo
Drug · Other
Lead sponsor
Sally E. Wenzel MD
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 6, 2026 · Synced Oct 2, 2026, 2:27 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Cognitive Effects of Citicoline on Attention in Healthy Mean and Women

NCT04967157
View directory record Official record
Conditions
Healthy
Interventions
Placebo supplement, Citicoline supplement
Dietary Supplement
Lead sponsor
Kirin Holdings Company, Limited
Industry
Eligibility
35 Years to 75 Years
Enrollment
148 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Addison, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 6, 2025 · Synced Oct 2, 2026, 2:27 AM EDT
Terminated Not applicable Interventional

Attention Bias Modification Treatment for Anxious Youth

NCT01979263
View directory record Official record
Conditions
Generalized Anxiety Disorder, Separation Anxiety Disorder, Social Phobia, Specific Phobia, Obsessive-Compulsive Disorder
Interventions
Attention Bias Modification Computer Task, Placebo Computer Task
Other
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
7 Years to 17 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
2
States / cities
New York, New York • White Plains, New York
Source: ClinicalTrials.gov public record
Updated Jul 30, 2019 · Synced Oct 2, 2026, 2:27 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Quantitative Mass Transfer of SFP-iron From Dialysate to Blood in CKD-HD Patients

NCT01894906
View directory record Official record
Conditions
Kidney Failure
Interventions
Soluble Ferric Pyrophosphate, Placebo
Drug · Other
Lead sponsor
Rockwell Medical Technologies, Inc.
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 16, 2015 · Synced Oct 2, 2026, 2:27 AM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Efficacy and Safety of Dasotraline in Children 6 to 12 Years Old With Attention-Deficit Hyperactivity Disorder (ADHD) in a Simulated Classroom Setting.

NCT03231800
View directory record Official record
Conditions
Attention-Deficit Hyperactivity Disorder (ADHD)
Interventions
dasotraline, Placebo
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
6 Years to 12 Years
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
8
States / cities
Newport Beach, California • Bradenton, Florida • Maitland, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 8, 2020 · Synced Oct 2, 2026, 2:27 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Atomoxetine for Attention Deficit Hyperactivity Disorder in Adolescents With Substance Use Disorder

NCT00399763
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder, Substance Abuse
Interventions
Atomoxetine, Placebo
Drug
Lead sponsor
Denver Health and Hospital Authority
Other
Eligibility
12 Years to 19 Years
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2008
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Jul 8, 2015 · Synced Oct 2, 2026, 2:27 AM EDT
Completed Phase 2 Interventional

Efficacy and Safety of NS2359 in Adults With Attention Deficit Hyperactivity Disorder

NCT00467428
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
NS2359, Placebo
Drug
Lead sponsor
NeuroSearch A/S
Industry
Eligibility
18 Years to 55 Years
Enrollment
126 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 30, 2007 · Synced Oct 2, 2026, 2:27 AM EDT
Recruiting Phase 2 Interventional

Prophylactic Intravenous Calcium Gluconate to Decrease Blood Loss at Time of Cesarean Delivery in Pregnant Patients at High Risk for Uterine Atony

NCT07217899
View directory record Official record
Conditions
Blood Loss, Surgical, Blood Loss, Postoperative, Uterine Atony
Interventions
Calcium Gluconate, Saline
Drug · Other
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older · Female only
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jul 24, 2026 · Synced Oct 2, 2026, 2:27 AM EDT
Terminated Phase 2 Interventional Results available

Evaluation of FDY-5301 in Major Trauma Patients in ICU

NCT04430283
View directory record Official record
Conditions
ICU Acquired Weakness
Interventions
FDY-5301, Placebo
Drug · Other
Lead sponsor
Faraday Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
5
States / cities
Torrance, California • Gainesville, Florida • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 13, 2023 · Synced Oct 2, 2026, 2:27 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Dose Escalation Study of Valortim® (MDX-1303) Administered Intravenously (IV) in Healthy, Normal Subjects

NCT01265745
View directory record Official record
Conditions
Anthrax
Interventions
Normal Saline for Injection, MDX1303
Drug · Biological
Lead sponsor
PharmAthene, Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Dec 9, 2013 · Synced Oct 2, 2026, 2:27 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Dietary Treatment of Crohn's Disease

NCT00343642
View directory record Official record
Conditions
Crohn's Disease, Inflammatory Bowel Disease
Interventions
Active fructo-oligosaccharide, Placebo fructo-oligosaccharide, Diet
Drug · Dietary Supplement
Lead sponsor
Rush University Medical Center
Other
Eligibility
18 Years to 80 Years
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
2
States / cities
Macon, Georgia • Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 9, 2021 · Synced Oct 2, 2026, 2:27 AM EDT
Completed Phase 4 Interventional Results available

Effects of Armodafinil on Cognition for Patients With Schizophrenia or Schizoaffective Disorder

NCT00373672
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
armodafinil (Nuvigil), placebo
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 65 Years
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 5, 2025 · Synced Oct 2, 2026, 2:27 AM EDT